ATRA is used in APL differentiation therapy; it converts PML/RARα from a transcriptional repressor to a transcriptional activator and induces its proteolysis (Dos et al., 2013; Nitto and Sawaki, 2014). This evidence concerns the gene PML and acute promyelocytic leukemia.